The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS - New Study
The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS Summary AFM28, a bispecific innate cell engager targeting CD123 and CD16A, demonstrates promising results in eliminating leukemic stem and progenitor cells (LSPCs) expressing CD123 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). By engaging natural killer (NK) cells…













